logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10729695 B1

PDFFull Text
Date of Patent:
Aug. 04, 2020

Filed:

Apr. 15, 2019

Amino, amido and heterocyclic compounds as modulators of rage activity and uses thereof

Applicants:

Ann Marie Schmidt, Franklin Lakes, NJ (US);

Ravichandran Ramasamy, Ardsley, NY (US);

Alexander Shekhtman, Glenmont, NY (US);

Vivek Rai, Allahabad, IN;

Michaele B. Manigrasso, New York, NY (US);

Inventors:

Ann Marie Schmidt, Franklin Lakes, NJ (US);

Ravichandran Ramasamy, Ardsley, NY (US);

Alexander Shekhtman, Glenmont, NY (US);

Vivek Rai, Allahabad, IN;

Michaele B. Manigrasso, New York, NY (US);

Assignees:

The Research Foundation for the State University of New York, Albany, NY (US);

New York University, New York, NY (US);

Attorney:

Hoffmann & Baron, LLP

Primary Examiner:

Rei Tsang Shiao

Int. Cl.
CPC ...
A61K 31/5377 (2006.01); C07D 319/20 (2006.01); C07D 213/75 (2006.01); C07D 277/28 (2006.01); C07D 239/42 (2006.01); C07D 403/04 (2006.01); C07D 403/06 (2006.01); C07D 487/14 (2006.01); C07D 417/04 (2006.01); C07D 277/42 (2006.01); A61K 31/4178 (2006.01); A61K 31/47 (2006.01); A61K 31/137 (2006.01); A61K 31/167 (2006.01); A61K 31/185 (2006.01); A61K 31/353 (2006.01); A61K 31/357 (2006.01); A61K 31/403 (2006.01); A61K 31/4045 (2006.01); A61K 31/4184 (2006.01); A61K 31/426 (2006.01); A61K 31/427 (2006.01); A61K 31/44 (2006.01); A61K 31/4439 (2006.01); A61K 31/454 (2006.01); A61K 31/4985 (2006.01); A61K 31/505 (2006.01); A61K 31/506 (2006.01); A61K 31/52 (2006.01);
U.S. Cl.
CPC ...
A61K 31/5377 (2013.01); A61K 31/137 (2013.01); A61K 31/167 (2013.01); A61K 31/185 (2013.01); A61K 31/353 (2013.01); A61K 31/357 (2013.01); A61K 31/403 (2013.01); A61K 31/4045 (2013.01); A61K 31/4178 (2013.01); A61K 31/4184 (2013.01); A61K 31/426 (2013.01); A61K 31/427 (2013.01); A61K 31/44 (2013.01); A61K 31/4439 (2013.01); A61K 31/454 (2013.01); A61K 31/47 (2013.01); A61K 31/4985 (2013.01); A61K 31/505 (2013.01); A61K 31/506 (2013.01); A61K 31/52 (2013.01); C07D 213/75 (2013.01); C07D 239/42 (2013.01); C07D 277/28 (2013.01); C07D 277/42 (2013.01); C07D 319/20 (2013.01); C07D 403/04 (2013.01); C07D 403/06 (2013.01); C07D 417/04 (2013.01); C07D 487/14 (2013.01);
Abstract

Amino, amido, and heterocyclic compounds are disclosed. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, diabetes complications, inflammation, and neurodegeneration, obesity, cancer, ischemia/reperfusion injury, cardiovascular disease and other diseases related to RAGE activity.

Find Patent Forward Citations

Loading…